ARTMS Inc. submits Drug Master File for the first ever multi-Curie production of Gallium-68 with ARTMS’ Solid Target Solution on medical cyclotrons
Burnaby, Canada, March 31, 2021 – ARTMS Inc. (ARTMS) is pleased to announce the submission of a Drug Master File (DMF) to the FDA for the high-volume production of Gallium-68 (68Ga) with ARTMS’ solid target technology in combination with a medical cyclotron. ARTMS’ proprietary QUANTM Irradiation system (QISTM) demonstrated world record production of over 10 […]
ARTMS to Advance ImmunoPET Imaging Isotope with Funding Support from Innovate BC
Vancouver, British Columbia. – March 2, 2021 – ARTMS Inc., the global leader in the development and commercialization of novel technologies and products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce that it received $300,000 funding from Innovate BC as part of its Ignite program. The funding will be combined […]
ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 with Cyclotron Produced Ga-68 Utilizing the QUANTM Irradiation System and Solid Targets
Burnaby, Canada and Petach Tikva, Israel, January 19, 2021 – ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system. The specially designed Prostate-Specific […]
ARTMS and Telix Pharmaceuticals Announce Successful Production of PSMA-11 with Cyclotron Produced Ga-68 from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced Telix’s prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)[1], using multi-Curie quantities of cyclotron-produced Gallium-68 (68Ga) via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target […]
Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
ARTMS Technology Featured in European Journal of Nuclear Medicine and Molecular Imaging Radiopharmacy and Chemistry
Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS and Solid Targets
Burnaby, Canada, December 22, 2020 – ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the […]
ARTMS Announces New Appointments to Executive Leadership Team
Company adds experienced executives to support the continued expansion of commercial
activities and focus on radiopharmaceutical innovator and manufacturer relationships
ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund
VANCOUVER, British Columbia, May 19, 2020—ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by Deerfield Management Company with continued investment from seed investor GHS Fund (Quark Venture […]
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
VANCOUVER, British Columbia and MELBOURNE, Australia, May 06, 2020 (GLOBE NEWSWIRE) — ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) […]
Global News – Metro Vancouver company makes advance in medical isotope technology
A Vancouver-area company has developed new technology to make it possible for hospital-based and other medical cyclotrons to produce Technetium-99, a key isotope for health care.